Spero Therapeutics (SPRO) Insider Trading & Ownership $0.91 +0.08 (+9.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Spero Therapeutics (NASDAQ:SPRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.52%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$57,336.41 Get SPRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Spero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SPRO Insider Buying and Selling by Quarter Spero Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/27/2024Ankit MahadeviaDirectorSell5,912$1.35$7,981.20 8/27/2024Sath ShuklaCEOSell2,757$1.35$3,721.95 8/27/2024Timothy KeutzerCOOSell2,213$1.35$2,987.55 8/5/2024Sath ShuklaCEOSell17,641$1.31$23,109.71 8/2/2024Sath ShuklaCEOSell14,800$1.32$19,536.00 (Data available from 1/1/2013 forward) SPRO Insider Trading Activity - Frequently Asked Questions Who is on Spero Therapeutics's Insider Roster? The list of insiders at Spero Therapeutics includes Ankit Mahadevia, Aquilo Capital Management, Llc, Kamal Hamed, Sath Shukla, and Timothy Keutzer. Learn more on insiders at SPRO. What percentage of Spero Therapeutics stock is owned by insiders? 4.52% of Spero Therapeutics stock is owned by insiders. Learn more on SPRO's insider holdings. Which Spero Therapeutics insiders have been selling company stock? The following insiders have sold SPRO shares in the last 24 months: Ankit Mahadevia ($41,609.26), Kamal Hamed ($50,159.92), Sath Shukla ($69,171.88), and Timothy Keutzer ($11,636.43). How much insider selling is happening at Spero Therapeutics? Insiders have sold a total of 123,060 Spero Therapeutics shares in the last 24 months for a total of $172,577.49 sold. Spero Therapeutics Key ExecutivesDr. Ankit Mahadevia M.D. (Age 43)MBA, Co-Founder & Chairman of the Board Compensation: $1.39MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Compensation: $1.12MMr. Timothy Keutzer (Age 56)Chief Operating Officer Compensation: $938.57k1 recent tradesMs. Esther P. Rajavelu (Age 45)CFO, Chief Business Officer & Treasurer Mr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 63)M.D., M.P.H., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies MacroGenics Insider Trades Inhibrx Insider Trades Artiva Biotherapeutics Insider Trades Neoleukin Therapeutics Insider Trades Zentalis Pharmaceuticals Insider Trades TuHURA Biosciences Insider Trades Inhibikase Therapeutics Insider Trades Cardiff Oncology Insider Trades Aclaris Therapeutics Insider Trades scPharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:SPRO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
